The Life Sciences Virtual Investor Forum takes place over two days, Wednesday, June 24 and Thursday, June 25, 2026, co-hosted by Virtual Investor Conferences and Zacks Small-Cap Research (@ZacksSmallCap), with live executive presentations from a range of life sciences companies. The Life Sciences Virtual Investor Forum is a B2i Digital (@b2idigital) Featured Conference. See event details and profiles of participating companies at b2idigital.com/vic-june-25th… To register and view the presentations: virtualinvestorconferences.c… Request a one-on-one meeting: app.axleaccess.com/public/ev… The two-day lineup spans clinical-stage biotechnology, rare-disease and oncology therapeutics, molecular diagnostics, medical devices, veterinary medicine, nutrition science, and AI-powered digital health. Schedule as of June 17 and subject to change: DAY ONE: Wednesday, June 24 9:30 AM ET: Protalix BioTherapeutics, Inc. (NYSE American: PLX) (@Protalix_Bio) 10:30 AM ET: MetaVia Inc. (Nasdaq: MTVA) (@MetaViaTx) 11:30 AM ET: CytoSorbents Corporation (Nasdaq: CTSO) (@CytoSorbents) 12:00 PM ET: PetVivo Holdings Inc. (OTCQX: PETV) (@PetVivo) 1:00 PM ET: Jaguar Health, Inc. (Nasdaq: JAGX) (@Jaguar_Health) 1:30 PM ET: Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (@RevivaPharma) 3:00 PM ET: 4DMedical Ltd. (OTC: FDMDF | ASX: 4DX) (@4dMedical) DAY TWO: Thursday, June 25 9:30 AM ET: Prostatype Genomics AB (OTCQB: PGABF | Nasdaq Stockholm: PROGEN) (@ProstatypeAB) 10:00 AM ET: Abingdon Health plc (OTCQB: ABDXF | LSE: ABDX) (@Abingdon_Health) 10:30 AM ET: Innovotech, Inc. (OTCQB: IOTCF | TSXV: IOT) 11:00 AM ET: Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: LABT) (@LakewoodAmedex) 11:00 AM ET: Nasus Pharma Ltd. (NYSE American: NSRX) (@NasusPharma) 11:30 AM ET: Kelyniam Global, Inc. (OTCID: KLYG) (@kelyniam) 12:00 PM ET: IMUNON, Inc. (Nasdaq: IMNN) 12:30 PM ET: Promino Nutritional Sciences Inc. (OTCID: MUSLF | CSE: MUSL) (@DrinkPromino) 1:00 PM ET: Envoy Medical Inc. (Nasdaq: COCH) (@EnvoyMedical) 1:30 PM ET: Coiled Therapeutics plc (OTCQB: COTXF | AIM: COIL) (@CoiledTx) 2:00 PM ET: Aspire Biopharma Holdings Inc. (Nasdaq: ASBP) 2:30 PM ET: Rocket Doctor AI Inc. (OTCQB: AIRDF | CSE: AIDR) (@rocketdoctor) 3:00 PM ET: Phio Pharmaceuticals Corp. (Nasdaq: PHIO) (@phio_pharma) 3:30 PM ET: aTyr Pharma, Inc. (Nasdaq: ATYR) (@aTyrNews) 4:00 PM ET: NuFarm Ltd. (OTC: NUFMF | ASX: NUF) (@NuseedGlobal) Virtual Investor Conferences is an OTC Markets Group (@OTCMarkets) Inc. property. Learn more at virtualinvestorconferences.c…. B2i Digital, The Capital Markets Matchmaker, will leverage its network of more than 1.7 million investors to help broaden visibility for presenting companies, in line with our mantra, From Marketing to Meetings. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.

The @b2idigital team is pleased to announce that Cadrenal Therapeutics, Inc. (Nasdaq: $CVKD) is participating in the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences @OTCMarkets and @ZacksSmallCap Research, on Thursday, March 12, 2026, at 3:00 PM EDT. The session will be moderated by David Bautz, PhD, Senior Analyst at Zacks Small Cap Research. The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: b2idigital.com/otc-life-scie… Virtual Investor Conferences brings together public companies and a global audience of retail and institutional investors for live executive presentations, Q&A sessions, and on-demand replays. The platform is open to public companies listed on NYSE, Nasdaq, TSX, CSE, ASX, and the OTC Markets. Cadrenal Therapeutics is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its lead program, CAD-1005, is a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder that has received Orphan Drug and Fast Track designations from the FDA as well as orphan drug status from the European Medicines Agency. The company’s broader pipeline includes tecarfarin, a Phase 3-ready oral vitamin K antagonist for patients with end-stage kidney disease and those with left ventricular assist devices, and frunexian, a parenteral clinical-stage Factor XIa inhibitor for use in acute hospital settings. Presenting on behalf of Cadrenal Therapeutics will be Quang X. Pham, Chairman and Chief Executive Officer, who founded the company and previously served as Chairman and CEO of Espero BioPharma, the prior sponsor of the tecarfarin IND. He holds a Bachelor of Arts in Economics from UCLA and served as a U.S. Marine Corps Officer. To register for this presentation, visit: virtualinvestorconferences.c… For more information about Cadrenal Therapeutics, visit: cadrenal.com/investors/ Content about any specific company was provided and approved by that company or is available in the public domain. B2i Digital, Inc. has not independently verified the accuracy of the information contained herein. The content contained herein is informational only, and no content contained herein shall be considered an offer to solicit the sale of any security or make a recommendation to purchase a security. B2i Digital is not a broker-dealer or investment adviser.